Diagnostic value of RAS mutations in Bethesda category IV thyroid nodules: a systematic review and meta-analysis
Authors:
Open Access
- 10 December 2025
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1685864
Abstract
Objectives: Thyroid nodules classified as Bethesda category IV cannot be diagnosed with fine-needle aspiration. RAS mutations have been linked to thyroid cancer, although it is still unclear if they are useful as a pre-operative molecular screening for this particular subgroup. In order to assess the diagnostic accuracy (sensitivity, specificity, AUC, etc.) of RAS mutations in identifying malignancy among Bethesda IV nodules and to ascertain whether this can consistently direct clinical decision-making and minimize non-essential interventions, we carried out a systematic review and meta-analysis using postoperative histopathology as the reference standard. Methods: A literature search of the PubMed, Embase, Cochrane Library, Web of Science and OVID databases was conducted. In all of the included studies, the diagnostic accuracy of RAS was compared with that of postoperative pathology, which was used as a standard. Data were pooled, and the sensitivity, specificity, area under the curve (AUC), positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) were calculated to estimate the accuracy of RAS. Results: A total of 10 studies were included after screening, comprising 913 cases of Bethesda Category IV nodules. Among them, there were 246 malignant lesions and 667 benign lesions. The pooled sensitivity of RAS mutations was 0.35 (95% CI, 0.29-0.41), and the specificity was 0.93 (95% CI, 0.90-0.95). The positive likelihood ratio was 3.46 (95% CI, 1.94-6.18), the negative likelihood ratio was 0.73 (95% CI, 0.60-0.89), and the AUC was 0.7954. Heterogeneity testing showed p2 = 58.5%, indicating significant heterogeneity. Conclusion: RAS mutations have a moderate diagnostic value in the diagnosis of Bethesda Category IV thyroid nodules. Despite the presence of some heterogeneity, the detection of RAS mutations may be helpful in guiding clinical decision-making and management strategies. Systematic Review Registration: https://www.crd.york.ac.uk/prospero , identifier CRD42024608197.Keywords
This publication has 27 references indexed in Scilit:
- Diagnosis of thyroid nodulesThe Lancet Diabetes & Endocrinology, 2022
- Preoperative Role of RAS or BRAF K601E in the Guidance of Surgery for Indeterminate Thyroid NodulesWorld Journal of Surgery, 2020
- RAS Proteins and Their Regulators in Human DiseaseCell, 2017
- The role of molecular diagnostic testing in the management of thyroid nodulesExpert Review of Molecular Diagnostics, 2017
- Preoperative detection of RAS mutation may guide extent of thyroidectomySurgery, 2017
- Correlation Between Histological Diagnosis and Mutational Panel Testing of Thyroid Nodules: A Two-Year Institutional ExperienceThyroid®, 2016
- Indeterminate Single Thyroid Nodule: Synergistic Impact of Mutational Markers and Sonographic Features in Triaging Patients to Appropriate SurgeryThyroid®, 2016
- 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid CancerThyroid®, 2016
- Centralized Molecular Testing for Oncogenic Gene Mutations Complements the Local Cytopathologic Diagnosis of Thyroid NodulesThyroid®, 2014
- Molecular genetics and diagnosis of thyroid cancerNature Reviews Endocrinology, 2011